In other news, digital health startup Forward has secured $100 million in funding and plans to offer telehealth services through its "CarePod" kiosks for $99 a month. Meanwhile, several companies have made significant moves in the healthcare sector, including AI drug discovery company Absci's agreement with Almirall, Resistomap's $2.1 million seed round for monitoring antibiotic-resistant microbes, and Selecta Biosciences' merger with Cartesian Therapeutics to focus on RNA cell therapies.
Key takeaways:
- Anthos Therapeutics has developed a new anticoagulant called abelacimab that has shown a 67% lower risk of bleeding compared to standard anticoagulants in phase 2 clinical trials. The company expects to move into phase three clinical trials with results expected in mid-2025.
- Digital health startup Forward has raised $100 million in funding and is offering telehealth services from its “CarePod” kiosks for $99 a month.
- Several healthcare startups have received funding or entered into agreements, including Layer Health, Absci, Resistomap, Selecta Biosciences, and Elucid.
- The FDA has approved a new medication by CorMedix called DefenCath to prevent a common type of infection seen in dialysis patients. The medication is expected to hit the market in the first quarter of 2024.